| Microorganism |
MIC50
(μg/ml) |
MIC90
(μg/ml) |
Range
(μg/ml) |
Antimicrobial |
Reference |
| Staphylococcus (GC 4549 + coagulase-negative + methicillin-resistant) |
- |
- |
<0.12 － ? |
Saccharomicin B  |
209 |
| Staphylococcus (GC 4549 + coagulase-negative + methicillin-resistant) |
- |
- |
0.5 － ? |
Vancomycin (Vancocyn, Lyphocin) |
209 |
| Staphylococcus (GC 4549 + coagulase-negative + methicillin-resistant) |
- |
- |
0.5 － ? |
Vancomycin (Vancocyn, Lyphocin) |
209 |
| Staphylococcus (GC 4549 + coagulase-negative + methicillin-resistant) |
- |
- |
16 － ? |
Piperacillin (Pipracil) |
209 |
| Staphylococcus (GC 6257 + coagulase-negative + methicillin-resistant) |
- |
- |
<0.12 － ? |
Ciprofloxacin (Cipro, Ciproxin, Ciprobay) |
209 |
| Staphylococcus (GC 6257 + coagulase-negative + methicillin-resistant) |
- |
- |
0.25 － ? |
Saccharomicin A |
209 |
| Staphylococcus (GC 6257 + coagulase-negative + methicillin-resistant) |
- |
- |
0.25 － ? |
Saccharomicin B |
209 |
| Staphylococcus (GC 6257 + coagulase-negative + methicillin-resistant) |
- |
- |
0.5 － ? |
Vancomycin (Vancocyn, Lyphocin) |
209 |
| Staphylococcus (GC 6257 + coagulase-negative + methicillin-resistant) |
- |
- |
2 － ? |
Piperacillin (Pipracil) |
209 |
| Staphylococcus (group A) |
0.015 |
0.03 |
≤0.007 － 0.125 |
Cefepime (Maxipime) |
113 |
| Staphylococcus (group A) |
0.015 |
0.03 |
≤0.007 － 0.125 |
Cefotaxime (Cephotaxime, Claforan) |
113 |
| Staphylococcus (group A) |
0.015 |
0.03 |
≤0.007 － 0.125 |
Ceftriaxone (Rocephin) |
113 |
| Staphylococcus (group A) |
0.015 |
0.03 |
≤0.007 － 0.5 |
Imipenem |
113 |
| Staphylococcus (group A) |
0.06 |
0.12 |
≤0.007 － 0.5 |
Cefoperazone (Cefobid) |
113 |
| Staphylococcus (group A) |
0.12 |
0.25 |
0.06 － 1 |
Ceftazidime (Ceptaz, Fortaz, Tanicef) |
113 |
| Staphylococcus (group A) |
0.12 |
0.25 |
0.06 － 1 |
Ceftazidime (Ceptaz, Fortaz, Tanicef) |
113 |
| Staphylococcus (group B) |
0.015 |
0.03 |
≤0.007 － 0.06 |
Imipenem |
113 |
| Staphylococcus (group B) |
0.03 |
0.06 |
0.015 － 0.125 |
Cefotaxime (Cephotaxime, Claforan) |
113 |
| Staphylococcus (group B) |
0.03 |
0.06 |
0.03 － 0.125 |
Ceftriaxone (Rocephin) |
113 |
| Staphylococcus (group B) |
0.06 |
0.12 |
0.03 － 0.125 |
Cefepime (Maxipime) |
113 |
| Staphylococcus (group B) |
0.12 |
0.25 |
0.06 － 0.15 |
Cefoperazone (Cefobid) |
113 |
| Staphylococcus (group B) |
0.5 |
0.5 |
0.25 － 2 |
Ceftazidime (Ceptaz, Fortaz, Tanicef) |
113 |
| Staphylococcus (group B) |
0.5 |
0.5 |
0.25 － 2 |
Ceftazidime (Ceptaz, Fortaz, Tanicef) |
113 |
| Staphylococcus (group G) |
0.007 |
0.015 |
≤0.007 － 0.06 |
Imipenem |
113 |
| Staphylococcus (group G) |
0.015 |
0.03 |
≤0.007 － 0.06 |
Cefotaxime (Cephotaxime, Claforan) |
113 |
| Staphylococcus (group G) |
0.03 |
0.03 |
0.015 － 0.06 |
Cefepime (Maxipime) |
113 |
| Staphylococcus (group G) |
0.03 |
0.06 |
≤0.007 － 0.06 |
Ceftriaxone (Rocephin) |
113 |
| Staphylococcus (group G) |
0.12 |
0.25 |
0.06 － 0.5 |
Cefoperazone (Cefobid) |
113 |